MBRX
$0.73
Moleculin Biotech CS
$.00
.03%
MBRX
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.10)
Revenue:  $0.00 Mil
Tuesday
Nov 10
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when MBRX reports earnings?
Beat
Meet
Miss

Where is MBRX's stock price going from here?
Up
Flat
Down
Stock chart of MBRX
Analysts
Summary of analysts' recommendations for MBRX
Score
Grade
Pivots
Resistance
$0.81
$0.78
$0.76

$0.73

Support
$0.71
$0.68
$0.66
Tweet
Growth
Description
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin Biotech, Inc. is based in Houston, TX.